CMPX Q4 2025 Earnings — Compass Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CMPXCompass Therapeutics, Inc.

$781M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

$0

Net Income

-$16M

EPS (Diluted)

$-0.09

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$220M

Total Liabilities

$23M

Stockholders' Equity

$197M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	$0	-$17M	+100.0%
Net Income	-$16M	-$15M	-4.5%